Trial · NCT07210723
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1 | 26 weeks | |
| Primary | Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1 | 26 weeks | |
| Secondary | Part 1: Change from Baseline (Day 1) to Week 26 in peak VO2 | 26 weeks | |
| Secondary | Part 1: Association between response in left ventricular global longitudinal strain and/or left atrial function index after 2 weeks of active treatment with placebo-adjusted Week 26 response in peak VO2 | 26 weeks | |
| Secondary | Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in overall population | 26 weeks | |
| Secondary | Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular ejection fraction | 26 weeks | |
| Secondary | Part 1 and 2: Change from Baseline (Day 1) to Week 26 in ventilatory efficiency | 26 weeks | |
| Secondary | Part 1 and 2: Change from Baseline (Day 1) to Week 26 in Kansas City Cardiomyopathy Questionnare (KCCQ-23) Clinical Summary Score | 26 weeks | All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. |
| Secondary | Part 1: Proportion of participants from Baseline (Day 1) to Week 26 who achieve at least a one-class improvement in New York Heart Association (NYHA) class | 26 weeks | NYHA is a system used to categorize the severity of heart failure symptoms based on a patient's functional capacity, where 1 indicates no symptoms or limitations and 4 indicates symptoms present at rest. |
| Secondary | Part 2: Change from Baseline (Day 1) to Week 26 in left atrial function index | 26 weeks | |
| Secondary | Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in the responder subgroup | 26 weeks | |
| Secondary | Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in overall population | 26 weeks | |
| Secondary | Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular global longitudinal strain | 26 weeks | |
| Secondary | Part 1 and 2: Percent change from Baseline (Day 1) to Week 26 in NT-proBNP concentrations | 26 weeks | |
| Secondary | Part 1 and 2: Characterization of peak (Cmax) of danicamtiv | 20 weeks | |
| Secondary | Part 1 and 2: Characterization of trough (Cmin) plasma concentrations of danicamtiv | 20 weeks | |
| Other | Part 1 and 2: Incidence and severity of treatment emergent adverse events, adverse events of special interest, serious adverse events and disease related events | 26 weeks | |
| Other | Incidence of abnormal findings in laboratory assessments, physical examinations, 12-lead ECGs, and vital signs | 26 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07210723/registered